These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19043919)

  • 1. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.
    Erickson AK; Seiwert S; Gale M
    Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes.
    Wang YZ; Li JL; Wang X; Zhang T; Ho WZ
    World J Gastroenterol; 2017 Aug; 23(32):5895-5903. PubMed ID: 28932081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
    Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
    PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
    Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
    Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.
    Lau DT; Negash A; Chen J; Crochet N; Sinha M; Zhang Y; Guedj J; Holder S; Saito T; Lemon SM; Luxon BA; Perelson AS; Gale M
    Gastroenterology; 2013 Feb; 144(2):402-413.e12. PubMed ID: 23123437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
    Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
    J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.
    Liu WL; Yang HC; Su WC; Wang CC; Chen HL; Wang HY; Huang WH; Chen DS; Lai MY
    PLoS One; 2012; 7(9):e43824. PubMed ID: 22962590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response.
    Bauhofer O; Ruggieri A; Schmid B; Schirmacher P; Bartenschlager R
    Gastroenterology; 2012 Aug; 143(2):429-38.e8. PubMed ID: 22522091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.
    Brownell J; Wagoner J; Lovelace ES; Thirstrup D; Mohar I; Smith W; Giugliano S; Li K; Crispe IN; Rosen HR; Polyak SJ
    J Hepatol; 2013 Oct; 59(4):701-8. PubMed ID: 23770038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.
    Liu WL; Yang HC; Hsu CS; Wang CC; Wang TS; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14799-14804. PubMed ID: 27930338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus interferon: a novel interferon for the treatment of hepatitis C.
    Heathcote J
    J Viral Hepat; 1998 Sep; 5 Suppl 1():13-8. PubMed ID: 9795924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.